Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

First-in-human phase I/II, open-label study of mRNA-2416 alone or combined with durvalumab in patients with advanced solid tumors and ovarian cancer

1 Jun 2025

Abstract excerpt

BACKGROUND: mRNA-2416 is a novel lipid nanoparticle-encapsulated messenger RNA (mRNA) encoding human OX40 ligand (OX40L) for intratumoral (Itu) injection. OX40L plus immune checkpoint inhibitor (ICI) increased preclinical antitumor activity, thus mRNA-2416 plus ICI may potentiate antitumor activity. METHODS: This first-in-human, phase I/II, open-label, multicenter study examined the safety, tolerability, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to PARP inhibition in cancer therapy
Share to RNA Interference and Gene Delivery
Share to RNA Research and Splicing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40515479
DOI: 10.1093/oncolo/oyaf115

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First-in-human phase I/II, open-label study of mRNA-2416 alone or combined with durvalumab in patients with advanced solid tumors and ovarian cancerPMID 40515479Read ↗

Biomarkers of mRNA vaccine efficacy derived from mechanistic modeling of tumor-immune interactionsSemantic proximity Read ↗

mRNA Vaccine Platforms and Lipid Nanoparticle Delivery Systems: Molecular Advances, Clinical Breakthroughs, and Regulatory Perspectives (2020–2025)Semantic proximity Read ↗

Intratumoral administration of mRNA-1273 vaccine delays melanoma growth in miceSemantic proximity Read ↗

Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPsSemantic proximity Read ↗

Spleen-targeted NeoPol-mL242 mRNA vaccine induces robust T-cell responses in a hepatocellular carcinoma modelSemantic proximity Read ↗

Cd73-LNPs promotes antitumor T-cell immunity via amplifying Tlr3-mediated immunostimulatory dendritic cell activationSemantic proximity Read ↗

Second generation of LNP based mRNA vaccine leads to a T cell–inflamed tumor microenvironment favorable for improving PD-1/PD-L1 blocking therapy and long-term immunity in a cold tumor modelSemantic proximity Read ↗

From structural design to delivery: mRNA therapeutics for cancer immunotherapySemantic proximity Read ↗

Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imagingSemantic proximity Read ↗

The Platform Technology Approach to mRNA Product Development and RegulationSemantic proximity Read ↗

Nanoparticle-mediated delivery of PD-L1 inhibitor enhances γδ T cell immunotherapy against metastatic ovarian cancer cellsSemantic proximity Read ↗

High-throughput <i>in vivo</i> screening using barcoded mRNA identifies lipid nanoparticles with extrahepatic tropism for cancer immunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.